SLC5A2 and heart failure: Unfortunately, this patient and those diagnosed previously still do not have access to disease-modifying therapy. The use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) has been shown to reduce a composite of all-cause mortality and heart failure hospitalizations in patients with CA-ATTR [12].